The Methylene Blue Secret: Starving Cancer, Fueling Life

Many people don't consider that cancer might be a 'power plant problem' rather than just a tumor issue. Dr. Prato explores how mitochondrial damage and its impact on energy production can lead to symptoms like fatigue, brain fog, and immune weakness. Understanding cellular health and metabolic health is crucial, as mitochondrial dysfunction can be a key driver of various diseases, including chronic fatigue syndrome.🎯 What You’ll Learn in This Episode:- Why mitochondria matter in cancer biology- The link between metabolism and immune function- How toxins and infections damage mitochondrial DNA- What methylene blue does in the electron transport chain- Why timing matters during chemotherapy- The role of CoQ10, NADH, and D-ribose in ATP production- How to support detox and redox balance- Why mitochondrial health influences long-term remission📍 Envita Medical Centers – Scottsdale, AZ🌐 Learn more: www.envita.com📞 Speak with a care coordinator: 866-830-4576“Energy isn’t just about feeling good — it’s about cellular survival.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493